Trial · NCT02858310
Adverse event totals15
The totals the trial posted for each group.
1 to 15 of 15
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 0 | 3 |
| Total, all-cause mortality | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 0 | 3 |
| Total, all-cause mortality | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 0 | 6 |
| Total, all-cause mortality | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 0 | 18 |
| Total, all-cause mortality | Participants Enrolled But Were Not Treated | 5 | 194 |
| Total, other adverse events | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 3 | 3 |
| Total, other adverse events | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 3 | 3 |
| Total, other adverse events | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 6 | 6 |
| Total, other adverse events | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 18 | 18 |
| Total, other adverse events | Participants Enrolled But Were Not Treated | 0 | 0 |
| Total, serious adverse events | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 3 | 3 |
| Total, serious adverse events | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 3 | 3 |
| Total, serious adverse events | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 5 | 6 |
| Total, serious adverse events | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 5 | 18 |
| Total, serious adverse events | Participants Enrolled But Were Not Treated | 0 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02858310/event-totals